Note: Pharmaceutical Specialties's revenues are gauged from an analysis of company filings.
Pharmaceutical Specialties's Income Statement (based on Industry Averages)
Pharmaceutical Specialties P&L
$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit
Trademark Applications
Trademark applications show the products and services that Pharmaceutical Specialties is developing and marketing.
Pharmaceutical Specialties doesn't have any recent trademark applications, indicating Pharmaceutical Specialties is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
ROBATHOL BATH OIL
10/30/2014
Z-BAR BAR SOAP
08/22/2014
VANIPLY Skin moisturizer for the face and body [; general purpose mentholated ointment not for medical use ]
04/13/2010
See all trademarks and details in the Full Report.
Market Share of Pharmaceutical Specialties's Largest Competitors
A competitive analysis shows these companies are in the same general field as Pharmaceutical Specialties, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Pharmaceutical Specialties.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Pharmaceutical Specialties and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.